Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India. For the full story, visit the source.
Health
Dr Reddy’s launches oral semaglutide biosimilar Obeda
Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India.
By BL Hyderabad Bureau· BusinessLine· 5 months ago· 2 min read
This summary is sourced from BusinessLine. Read the full article at:BusinessLine